# Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

> **NCT03045393** · PHASE1 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Breast Cancer Triple Negative

## Interventions

- **DRUG:** Mirvetuximab Soravtansine (IMGN853)

## Key facts

- **NCT ID:** NCT03045393
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04-17
- **Primary completion:** 2018-02-28
- **Final completion:** 2018-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate enrollment
- **Last updated:** 2018-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045393, "Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03045393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*